SCHEMBL474688

SCHEMBL474688

CCCN[C@@H](CCS)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 2/20 0.41
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
NFKB1 P19838 1/20 0.39
PTGS2 P35354 1/20 0.39
THPO P40225 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NOD1 Q9Y239 2/20 0.38
CHRM1 P11229 1/20 0.37
AKR1A1 P14550 1/20 0.37
CHRM3 P20309 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1A P35348 1/20 0.37
HRH1 P35367 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474687 1.00 GGT1 (0.41) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL5867413 1.00 GGT1 (0.41) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL5904142 0.91 GGT1 (0.36) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL3386652 0.89 NOD1 (0.49) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL3386644 0.89 NOD1 (0.49) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL8627016 0.87 GGT1 (0.46) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL3260932 0.87 NOD1 (0.51) GGT1MAPTSMN1; SMN2NOD1FOLH1
SCHEMBL11162391 0.87 NOD1 (0.51) GGT1MAPTSMN1; SMN2NOD1FOLH1
SCHEMBL3260935 0.87 NOD1 (0.51) GGT1MAPTSMN1; SMN2NOD1FOLH1
SCHEMBL10630157 0.85 NOD1 (0.53) MAPTNOD1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190119322-A1 PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-04-25 US claimed
WO-2018128826-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2018-07-12 WO claimed
WO-2018006063-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2018-01-04 WO claimed
WO-2017189860-A1 PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-02 WO claimed
US-20120093726-A1 Radiolabeled Fluorine Derivatives of Methionine CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) 2012-04-19 US claimed
EP-2411360-A1 RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE CRC For Biomedical Imaging Development Ltd (AU) 2012-02-01 EP claimed
WO-2010108210-A1 RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) 2010-09-30 WO claimed
EP-1379214-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING SAME L'OREAL, S.A. (FR) 2004-01-14 EP claimed
US-20020159962-A1 Hair relaxer compositions comprising at least one hydroxide compound and at least one activating agent, and methods of using the same L'OREAL S.A. (FR) 2002-10-31 US claimed
WO-2002067875-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING THE SAME L'OREAL S.A. (FR) 2002-09-06 WO claimed
US-12540162-B2 Preparation of functional homocysteine residues in polypeptides and peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-02-03 US disclosed
US-20240092833-A1 PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-03-21 US disclosed
US-11732008-B2 Preparation of functional homocysteine residues in polypeptides and peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-22 US disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 US disclosed
US-20230165970-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-01 US disclosed
WO-2010108210-A1 RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) 2010-09-30 WO disclosed
US-7118736-B2 Hair relaxer compositions comprising at least one hydroxide compound and at least one activating agent, and methods of using the same L'OREAL (FR) 2006-10-10 US disclosed
EP-1379214-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING SAME L'OREAL, S.A. (FR) 2004-01-14 EP disclosed
US-20020159962-A1 Hair relaxer compositions comprising at least one hydroxide compound and at least one activating agent, and methods of using the same L'OREAL S.A. (FR) 2002-10-31 US disclosed
WO-2002067875-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING THE SAME L'OREAL S.A. (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119322-A1 PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES BHMT2, BHMT, PTMS GGT1 262/4885KDM4E 1957/4885MAPT 4077/4885
US-20120093726-A1 Radiolabeled Fluorine Derivatives of Methionine BHMT2, MGMT, AHCY GGT1 251/4885KDM4E 2789/4885MAPT 3947/4885
US-12540162-B2 Preparation of functional homocysteine residues in polypeptides and peptides PTMS, AHCY, BHMT2 GGT1 879/4885KDM4E 2127/4885MAPT 2741/4885
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A GGT1 1269/4885KDM4E 4734/4885MAPT 3999/4885
US-11732008-B2 Preparation of functional homocysteine residues in polypeptides and peptides BHMT2, BHMT, PTMS GGT1 262/4885KDM4E 1957/4885MAPT 4077/4885
US-20230165970-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A GGT1 1269/4885KDM4E 4734/4885MAPT 3999/4885
US-20240092833-A1 PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES BHMT2, BHMT, PTMS GGT1 262/4885KDM4E 1957/4885MAPT 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.